Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM

Pasquale L. Fedele, MBBS PhDFRACP FRCPA, Yang Liao, PhD, Jianan Gong, PhD, Mark van Delft, PhD, Michael S.Y. Low, MBBS PhDFRACP FRCPA, Lin Tai, PhD, Marco J Herold, PhD, Julie Tellier, PhD, George Grigoriadis, MBBS PhDFRACP FRCPA, David C.S. Huang, MBBS MRCP PhD, Wei Shi, PhD, Stephen Nutt, PhD, Simon Willis, PhD

Blood (2019) 134 (Supplement_1): 3103.

https://doi.org/10.1182/blood-2019-126417

Published: 2019

Journal Articles

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Brenda J Chyla, PhD, Relja Popovic, PhD, Charles Lu, PhD, Fengjiao Dunbar, PhD, Danjuma Quarless, PhD, Kenneth Robinson, MS, Scott Warder, PhD, Amanda Jacobson, PhD, Lang Zhou, PhD, Andrew Souers, PhD, Jeffrey Waring, PhD, Anahita Bhathena, PhD, Joel D. Leverson, PhD, Su Young Kim, MD PhD

Blood (2019) 134 (Supplement_1): 172.

https://doi.org/10.1182/blood-2019-127458

Published: 2019

Journal Articles

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Destini Gibbs, Herman Van Besien, BA, Stephenson Regan, Ankur Singh, PhD, Matthew Teater, Ethel Cesarman, MD PhD, Ari Melnick, MD, Lisa Giulino Roth, MD

Blood (2019) 134 (Supplement_1): 304.

https://doi.org/10.1182/blood-2019-126790

Published: 2019

Journal Articles

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Trisha Kissoon, MD MBA

Blood (2019) 134 (Supplement_1): 5062.

https://doi.org/10.1182/blood-2019-129511

Published: 2019

Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Martine Amiot, PhD

Blood (2019) 134 (Supplement_1): SCI-11.

https://doi.org/10.1182/blood-2019-121103

Published: 2019

Journal Articles

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Lai N Chan, PhD, Christian Hurtz, PhD, Huimin Geng, PhD, Erica Ballabio, Gang Xiao, PhD, Gauri Deb, MS, PhD, Haytham Khoury, MD PhD, Scott A. Armstrong, MD PhD, Patricia Ernst, PhD, Ari Melnick, MD, Tom Arthur Milne, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 1239.

https://doi.org/10.1182/blood-2019-131565

Published: 2019

Journal Articles

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Zhigang Cai, PhD, Baskar Ramdas, PhD, Jonathan Kotzin, Martin P. Carroll, MD, Gerald Wertheim, MD, PhD, Adam Williams, Jorge Henao-Mejia, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 915.

https://doi.org/10.1182/blood-2019-130653

Published: 2019

Journal Articles

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

Brandon Chen, Wong Pamela, B.S., Daniel Auclair, PhD, Jonathan J Keats, PhD, Paul Secrist, PhD, Justin Cidado, PhD, Adriana E. Tron, PhD, Christine M Dunham, PhD, Sagar Lonial, MD, Joseph Opferman, PhD, Shannon M Matulis, PhD, Lawrence H. Boise, PhD

Blood (2018) 132 (Supplement 1): 951.

https://doi.org/10.1182/blood-2018-99-113444

Published: 2018

Journal Articles

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

Hearn Jay Cho, MD, Anna Huo-Chang Mei, MS, Kaity Tung, BS, Jessie Han, Deepak Perumal, PhD, Jonathan J Keats, PhD, Daniel Auclair, PhD, Ajai Chari, MD, Sundar Jagannath, MD, Samir Parekh, MD, Alessandro Lagana, PhD

Blood (2018) 132 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2018-99-118692

Published: 2018

Journal Articles

miR106a-363 Cluster Has Oncogenic Potential in Childhood T-Cell Acute Lymphoblastic Leukemia

Monika Drobna, MSc, Bronislawa Szarzynska-Zawadzka, Maria Kosmalska, Roman Jaksik, PhD, Tomasz Szczepanski, MD PhD, Michał Witt, MD PhD, Małgorzata Dawidowska, PhD

Blood (2018) 132 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2018-99-111103

Published: 2018

Journal Articles

Haploinsufficiency for NR3C1 Drives Glucocorticoid Resistance By Inactivation the PI3K/AKT/GSK3β/Bim Pathway in Adult Acute Lymphoblastic Leukemia

Xiao Haowen, MD PhD, Yingying Ding, Yang Gao, Limengmeng Wang, PhD, Huafang Wang, Xiaohong Yu, He Huang, MD PhD

Blood (2018) 132 (Supplement 1): 1328.

https://doi.org/10.1182/blood-2018-99-120089

Published: 2018

Journal Articles

Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort

Steven M. Foltz, MS, Qingsong Gao, PhD, Christopher J. Yoon, MPhil, Amila Weerasinghe, PhD, Hua Sun, PhD, Lijun Yao, MS, Mark A. Fiala, BS, Daniel R. Kohnen, MBA, Justin King, BS, Yeong Seok Ju, MD PhD, John F. DiPersio, MD PhD, Ravi Vij, MBBS, Li Ding, PhD

Blood (2018) 132 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2018-99-117245

Published: 2018

Journal Articles

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Hearn Jay Cho, MD PhD, Anna Huo-Chang Mei, MS, Jami Fukui, MD, Kaity Tung, BS, Deepak Perumal, PhD, Violetta Leshchenko, PhD, Alessandro Lagana, PhD, Seunghee Kim-Schultze, PhD, Ajai Chari, Sundar Jagannath, MD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 4332.

https://doi.org/10.1182/blood.V130.Suppl_1.4332.4332

Published: 2017

Journal Articles

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Clifford J. Whatcott, PhD, James M Bogenberger, PhD, Wontak Kim, Hillary Haws, Nanna Hansen, M.S., Devora Delman, B.S., Lisa Sproat, MD MSW, Jeanne Palmer, MD, Ruben A. Mesa, MD, Peter Peterson, PhD, Adam Siddiqui-Jain, PhD, Steven Weitman, MD PhD, David J. Bearss, PhD, Steven L. Warner, PhD, Raoul Tibes, MD PhD

Blood (2016) 128 (22): 1652.

https://doi.org/10.1182/blood.V128.22.1652.1652

Published: 2016

Journal Articles

Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression

Lara Rizzotto, PhD, Arianna Bottoni, PhD, Tzung-Huei Lai, PhD, Chaomei Liu, BS, Pearlly S Yan, PhD, Hatice G Ozer, PhD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD, Christopher C Oakes, PhD, James S. Blachly, MD, Deepa Sampath, PhD

Blood (2016) 128 (22): 2705.

https://doi.org/10.1182/blood.V128.22.2705.2705

Published: 2016

Journal Articles

Identification of Imatinib-Sensitizing Genes in Chronic Myeloid Leukemia with a Genome-Scale Crispr Knock-out Screen

Matthieu Lewis, MD, Valerie Prouzet-Mauleon, Elodie Richard, Beatrice Turcq, Richard Iggo, MD PhD, Francois-xavier Mahon, MD PhD

Blood (2016) 128 (22): 4233.

https://doi.org/10.1182/blood.V128.22.4233.4233

Published: 2016

Journal Articles

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Kaiming Sun, PhD, Ruzanna Atoyan, MD, Mylissa A Borek, MS, Steven Dellarocca, MS, Garrett Rhyasen, PhD, Ali Fattaey, PhD, David P Tuck, MD

Blood (2016) 128 (22): 4184.

https://doi.org/10.1182/blood.V128.22.4184.4184

Published: 2016

Journal Articles

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Susana Hernández-García, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Luis A Corchete, Teresa Paíno, Ana Alicia López-Iglesias, Esperanza Macarena Algarín, Mercedes Garayoa, Brian Tunquist, Norma C Gutierrez, Maria-Victoria Mateos, MD PhD, Enrique M Ocio

Blood (2015) 126 (23): 1801.

https://doi.org/10.1182/blood.V126.23.1801.1801

Published: 2015

Journal Articles

Targeting F2r/Beta-Catenin/JNK Signaling for Leukemia Stem Cell Eradication

Jennifer Lynch, PhD, Hangyu Yi, BA, Brendon Martinez, BA, Florida Voli, MSc, Jenny Yingzi Wang, PhD

Blood (2015) 126 (23): 3061.

https://doi.org/10.1182/blood.V126.23.3061.3061

Published: 2015

Journal Articles

BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells

Baohua Sun, MD PhD, Warren Fiskus, PhD, Dyana T Saenz, Stephanie Krieger, Liang Zhang, MD PhD, Simrit Parmar, MD, Michael Wang, MD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 3704.

https://doi.org/10.1182/blood.V126.23.3704.3704

Published: 2015

NARROW

Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM

Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

Combined EZH2 and BCL2 Inhibitors As Precision Therapy for Genetically Defined DLBCL Subtypes

Using Pharmacogenomics Testing to Optimize Care in Children with Acute Hematologic Malignancies

Targeting Bcl-2 Proteins in Myeloma

Rationale for Targeting BCL6 in MLL-Rearranged B-ALL

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function

MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21 Cip1

miR106a-363 Cluster Has Oncogenic Potential in Childhood T-Cell Acute Lymphoblastic Leukemia

Haploinsufficiency for NR3C1 Drives Glucocorticoid Resistance By Inactivation the PI3K/AKT/GSK3β/Bim Pathway in Adult Acute Lymphoblastic Leukemia

Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort

MAGE-a Inhibits Apoptosis in Multiple Myeloma through Regulation of Bim and PUMA

Alvocidib Potentiates the Activity of Venetoclax in Preclinical Models of Acute Myeloid Leukemia

Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression

Identification of Imatinib-Sensitizing Genes in Chronic Myeloid Leukemia with a Genome-Scale Crispr Knock-out Screen

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Mechanisms Underlying the Synergistic Interaction of Filanesib with Pomalidomide and Dexamethasone (FPD) in Multiple Myeloma

Targeting F2r/Beta-Catenin/JNK Signaling for Leukemia Stem Cell Eradication

BET Protein Bromodomain Antagonist-Based Combinations Exert Synergistic Pre-Clinical Activity Against Ibrutinib-Sensitive or -Resistant Human Mantle Cell Lymphoma (MCL) Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only